Erratum to: Impacts of Patient Characteristics on the Effectiveness of Landiolol in AF/AFL Patients Complicated with LV Dysfunction: Subgroup Analysis of the J-Land Study

[1]  W. Shimizu,et al.  Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study). , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[2]  P. Ponikowski,et al.  Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. , 2013, Journal of the American College of Cardiology.

[3]  Piotr Ponikowski,et al.  Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial , 2013, The Lancet.

[4]  S. Werns.  Effect of Nesiritide in Patients with Acute Decompensated Heart Failure , 2012 .

[5]  M. Kawana,et al.  Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. , 2010, American heart journal.

[6]  T. Ikeda,et al.  Effects of landiolol, an ultra-short-acting beta1-selective blocker, on electrical storm refractory to class III antiarrhythmic drugs. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[7]  JCSJointWorkingGroup.  Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[8]  A. Takeshita,et al.  Effects of atrial fibrillation on long-term outcomes in patients hospitalized for heart failure in Japan: a report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[9]  A. Takeshita,et al.  Chronic Kidney Disease as an Independent Risk for Long-Term Adverse Outcomes in Patients Hospitalized With Heart Failure in Japan , 2009 .

[10]  H. Shimokawa,et al.  Prognostic importance of chronic kidney disease in Japanese patients with chronic heart failure. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[11]  K. Aaronson,et al.  Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. , 2005, JAMA.

[12]  K. Aaronson,et al.  Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure , 2005, Circulation.

[13]  K. Adams,et al.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.

[14]  W. Maisel,et al.  Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. , 2003, The American journal of cardiology.

[15]  G. Kay,et al.  Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. , 1997, Journal of the American College of Cardiology.